SynAct Pharma AB (SYNACT) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.170x

Based on the latest financial reports, SynAct Pharma AB (SYNACT) has a cash flow conversion efficiency ratio of -0.170x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-32.95 Million ≈ $-3.55 Million USD) by net assets (Skr193.75 Million ≈ $20.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can SynAct Pharma AB fund operations to measure how many days the company can operate on defensive assets alone.

SynAct Pharma AB - Cash Flow Conversion Efficiency Trend (2016–2025)

This chart illustrates how SynAct Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

SynAct Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of SynAct Pharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Jayant Agro Organics Limited NSE:JAYAGROGN	-0.075x
Kawan Food Bhd KLSE:7216	0.001x
Cheviot Company Limited NSE:CHEVIOT	0.072x
Jinhui Shipping and Transportation Limited OL:JIN	0.038x
Grupo Mexicano de Desarrollo S.A.B MX:GMD	0.036x
Birla Cable Limited NSE:BIRLACABLE	-0.019x
Demco Public Company Limited BK:DEMCO	0.015x
Welspun Investments and Commercials Limited NSE:WELINV	-0.002x

Annual Cash Flow Conversion Efficiency for SynAct Pharma AB (2016–2025)

The table below shows the annual cash flow conversion efficiency of SynAct Pharma AB from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see SYNACT stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr170.29 Million ≈ $18.33 Million	Skr-97.33 Million ≈ $-10.47 Million	-0.572x	-37.23%
2024-12-31	Skr214.17 Million ≈ $23.05 Million	Skr-89.20 Million ≈ $-9.60 Million	-0.416x	+26.75%
2023-12-31	Skr176.19 Million ≈ $18.96 Million	Skr-100.18 Million ≈ $-10.78 Million	-0.569x	+38.81%
2022-12-31	Skr126.52 Million ≈ $13.62 Million	Skr-117.56 Million ≈ $-12.65 Million	-0.929x	+70.17%
2021-12-31	Skr20.87 Million ≈ $2.25 Million	Skr-65.00 Million ≈ $-6.99 Million	-3.115x	-48.68%
2020-12-31	Skr15.87 Million ≈ $1.71 Million	Skr-33.24 Million ≈ $-3.58 Million	-2.095x	-75.44%
2019-12-31	Skr13.50 Million ≈ $1.45 Million	Skr-16.12 Million ≈ $-1.74 Million	-1.194x	+49.15%
2018-12-31	Skr10.31 Million ≈ $1.11 Million	Skr-24.21 Million ≈ $-2.61 Million	-2.348x	-76.25%
2017-12-31	Skr12.91 Million ≈ $1.39 Million	Skr-17.20 Million ≈ $-1.85 Million	-1.332x	-144.84%
2016-12-31	Skr27.08 Million ≈ $2.91 Million	Skr-14.73 Million ≈ $-1.59 Million	-0.544x	--

About SynAct Pharma AB

ST:SYNACT Sweden Biotechnology

Market Cap

$70.27 Million

Skr652.94 Million SEK

Market Cap Rank

#20673 Global

#372 in Sweden

Share Price

Skr11.66

Change (1 day)

+9.38%

52-Week Range

Skr10.66 - Skr24.95

All Time High

Skr143.40